Acura Pharmaceuticals, Inc. Release: FDA Posts Briefing Documents for April 22nd Joint Advisory Committee Meeting on Acurox(R)

PALATINE, Ill., April 20, 2010 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the April 22, 2010 joint meeting of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management Advisory Committees meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.